Correspondence 0001104659-23-009560 from YS Biopharma Co., Ltd. (LSB, LSBPW) (CIK 0001946399) (LSBCF)
YS Biopharma Co., Ltd. (LSB, LSBPW) (CIK 0001946399)
Date: Feb. 2, 2023 · CIK: 0001946399 · Accession: 0001104659-23-009560
AI Filing Summary & Sentiment
File numbers found in text: 333-269031
Letter
Via EDGAR Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: YishengBio Co., Ltd (CIK No. 0001946399) Registration Statement on Form F-4 (File No. 333-269031)
Dear Ms. Li Xiao, Ms. Connell, Mr. McNamara and Mr. Drory,
Pursuant to Rule 461 of Regulation C (“Rule 461”) promulgated under the Securities Act of 1933, as amended, YishengBio Co., Ltd (the “Company”) hereby requests that the effectiveness of the above-referenced registration statement on Form F-4, as amended (the “F-4 Registration Statement”), be accelerated to, and that the F-4 Registration Statement become effective at, 4:00 p.m., Eastern Time on February 7, 2023 or as soon thereafter as practicable.
If there is any change in the acceleration request set forth above, the Company will promptly notify you of the change, in which case the Company may be making an oral request of acceleration of the effectiveness of the F-4 Registration Statement in accordance with Rule 461. Such request may be made by an executive officer of the Company or by any attorney from the Company’s U.S. counsel, Wilson Sonsini Goodrich & Rosati, Professional Corporation.
[Signature page follows]
Very truly yours,
YishengBio Co., Ltd
Show Raw Text
CORRESP
1
filename1.htm
February 2, 2023
Via EDGAR
Ms. Li Xiao
Ms. Angela Connell
Mr. Jimmy McNamara
Mr. Jason Drory
U.S. Securities & Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re: YishengBio Co., Ltd (CIK No. 0001946399)
Registration Statement on Form F-4 (File
No. 333-269031)
Dear Ms. Li Xiao, Ms. Connell, Mr. McNamara and
Mr. Drory,
Pursuant to Rule 461 of Regulation C (“Rule
461”) promulgated under the Securities Act of 1933, as amended, YishengBio Co., Ltd (the “Company”) hereby
requests that the effectiveness of the above-referenced registration statement on Form F-4, as amended (the “F-4 Registration
Statement”), be accelerated to, and that the F-4 Registration Statement become effective at, 4:00 p.m., Eastern Time on February
7, 2023 or as soon thereafter as practicable.
If there is any change in the acceleration request
set forth above, the Company will promptly notify you of the change, in which case the Company may be making an oral request of acceleration
of the effectiveness of the F-4 Registration Statement in accordance with Rule 461. Such request may be made by an executive officer of
the Company or by any attorney from the Company’s U.S. counsel, Wilson Sonsini Goodrich & Rosati, Professional Corporation.
[Signature page follows]
Very truly yours,
YishengBio Co., Ltd
By:
/s/ Yi Zhang
Name:
Yi Zhang
Title:
Director and Chairperson